An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 26 Nov 2016
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Acronyms THETIS
- Sponsors Novartis Pharma A.G.
- 09 Jul 2016 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
- 09 Jul 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
- 08 Dec 2015 Results (n=134) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.